BioAtla of San Diego and Beijing Raises $30 Million from China Investors

BioAtla LLC, a San Diego-Beijing biotech, raised $30 million in an equity investment from an undisclosed group of China investors. The capital will be used to develop BioAtla's pipeline of Conditionally Active Biologic (CAB) antibody therapeutics. BioAtla characterized the transaction as a strategic investment that will further the company's plans to form collaborations with China companies. The collaborations will develop BioAtla therapies for the China market. The investor group has contacts in China, an important feature of the deal, said BioAtla. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.